← Stocks · INO record
Signal record & history · Trifecta Signals
Inovio has been flagged by the Trifecta screener 6 times since 2022. 5 signals confirmed; the median confirmed signal is down 92.1% since its Early Signal.
Price refreshes every trading day after the close.
Full interactive chart ↗ · partner link
Daily closes · through the most recent close
Price history from Jan 2018 · Signal tracking began Jan 2022
Headline statistics: confirmed signals only, measured from the confirmation price.
First signal Jan 2022 · Latest May 2023 · Confirmed 5 of 6 Early · Latest close in the chart data: Wed, Nov 4, 2026
Groups are mutually exclusive — every confirmed signal sits in exactly one.
Since January 2022, Inovio has had six Early signals, five confirmed. Three of the five decided signals gained +10% within 90 days, and zero of five finished ahead of the S&P 500 since confirmation. Four signals carried a caution flag. One Early signal never confirmed and counts in no statistic.
Every Early signal in the record, newest first.
Members see every signal below, and the group mix above.
Membership unlocks the complete signal timeline for INO and every other stock in the record — group tags, caution flags, and the full screener.
Already a member? Sign in and this page unlocks.
Inovio Pharmaceuticals sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Its market value of about $87 million places it in the small-cap group.
The strongest run on Inovio Pharmaceuticals’ record followed a confirmation in May 2022, gaining about 26% over the following 90 days. Another example came in October 2022, when a signal landed in the Downtrend group and the shares fell about 15% over the next 90 days. On classification, its latest signal was rated Low Quality, revenue was growing by about 535% at the time, and it sat in the small-cap group when that signal fired.
The stock closed Wednesday, November 4 at $1.62, down 2.4% on the day. The last five sessions span about $0.60 to about $1.89.
